As a consequence, these two BRAF-targeted agents achieved a considerable increased response rate, from 5% to 48%, with a single-agent administration (vemurafenib) [11], with complete regression of the tumor registered in some patients [12,13,14]. Here, BRAF is linked to neoplasm.